Navigation Links
Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development
Date:1/15/2014

Sunnyvale, CA (PRWEB) January 15, 2014

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Lupin Limited, one of India’s top five pharmaceutical companies, has received delivery of Freeslate’s CM Protégé PharmD System for high throughput solid form screening.

Lupin, headquartered in Mumbai, India, is focused on a wide range of quality, affordable generic and branded formulations and Active Pharmaceutical Ingredients (APIs) for the developed and developing markets of the world. Lupin has selected Freeslate’s CM Protégé PharmD System to accelerate polymorph screening, automating a formerly manual process and thereby increasing their throughput. The company expects to be able to perform more experiments with less material to support the expansion of their Novel Drug Discovery and Development Program.

“We are looking forward to using Freeslate’s CM Protégé PharmD System to accelerate our Novel Drug Discovery and Development Program,” said Mr. Raj Khamboj, President NDDS at Lupin. “We believe we will achieve a ten-fold improvement in throughput using the new system resulting in significant new discoveries that provide real benefits to patients.”

“Our CM Protégé PharmD System brings exciting capabilities to solid form screening and we’re pleased that Lupin sees it as a powerful tool for accelerating their development activities,” said John S. Senaldi, President and CEO of Freeslate. “As we focus on expansion in Asia and India, the CM Protégé PharmD System opens up opportunities for many more labs to adopt Freeslate’s cutting edge technology.”

Freeslate’s CM Protégé PharmD System brings the benefits of high throughput solid and solubility screening to a broader range of researchers with an easy-to-use, fully automated platform. The System can evaluate up to 384 crystallization conditions per run to rapidly turn around solid form screening projects. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass Universal Substrate without any manual manipulation of fragile crystals. Other analyses and additional experiments, such as solid form stability, can also be conducted directly on the glass Universal Substrate. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.

The CM Protégé PharmD System uses Freeslate’s Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its logical, recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11484957.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lupin Receives FDA Approval for Generic LYRICA(R)
2. Lupin élargit sa gamme
3. Lupin weitet Marken-Portfolio aus
4. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
5. Netsmart Selects Overland Park, Kansas, for New Office
6. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
7. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
8. Aesthetics Pharmaceutical Company Selects 360 Vantage Closed Loop Marketing Solution for Apple iPad
9. Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type
10. Bellicum Selects DATATRAK Solution for Drug Program
11. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, ... , a leading digital health company, and ... of telemedicine and remote patient monitoring, announce they ... reimbursements.  DN Telehealth maximizes collaboration ... real-time, extending consultations beyond a physical clinical setting ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift ... new partnership with Compass Research . GGI's mission is to advance global health ... a child in need in honor of each clinical trial volunteer. The vision of ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):